This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Wall Street Analysts Think LifeStance Health (LFST) Could Surge 30.49%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for LifeStance Health (LFST) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 33.38% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 33.4% in LifeStance Health (LFST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
LifeStance Health Group (LFST) Reports Break-Even Earnings for Q3
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of +100.00% and +2.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About LifeStance Health (LFST) Rating Upgrade to Strong Buy
by Zacks Equity Research
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of +66.67% and +0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
CSW, ASAN, and others show rising P/E trends -- suggesting breakout potential backed by strong earnings surprises.
LifeStance Health (LFST) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
After Plunging 9.9% in 4 Weeks, Here's Why the Trend Might Reverse for LifeStance Health (LFST)
by Zacks Equity Research
The heavy selling pressure might have exhausted for LifeStance Health (LFST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Think LifeStance Health (LFST) Could Surge 45.04%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 45% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LifeStance Health (LFST) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.